HomeCompareSLMXF vs PFE

SLMXF vs PFE: Dividend Comparison 2026

SLMXF yields 4065.04% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLMXF wins by $8383345271821.52M in total portfolio value
10 years
SLMXF
SLMXF
● Live price
4065.04%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8383345271821.57M
Annual income
$7,996,384,829,748,816,000.00
Full SLMXF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SLMXF vs PFE

📍 SLMXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLMXFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLMXF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLMXF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLMXF
Annual income on $10K today (after 15% tax)
$345,528.46/yr
After 10yr DRIP, annual income (after tax)
$6,796,927,105,286,493,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SLMXF beats the other by $6,796,927,105,286,471,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLMXF + PFE for your $10,000?

SLMXF: 50%PFE: 50%
100% PFE50/50100% SLMXF
Portfolio after 10yr
$4191672635910.81M
Annual income
$3,998,192,414,874,421,000.00/yr
Blended yield
95.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SLMXF
No analyst data
Altman Z
-1.2
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLMXF buys
0
PFE buys
0
No recent congressional trades found for SLMXF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLMXFPFE
Forward yield4065.04%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8383345271821.57M$49.6K
Annual income after 10y$7,996,384,829,748,816,000.00$26,258.71
Total dividends collected$8356966171072.82M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLMXF vs PFE ($10,000, DRIP)

YearSLMXF PortfolioSLMXF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$417,204$406,504.07$9,153$693.39+$408.1KSLMXF
2$16,296,422$15,850,013.87$8,593$849.25+$16.29MSLMXF
3$596,052,062$578,614,890.14$8,336$1,066.78+$596.04MSLMXF
4$20,416,476,221$19,778,700,514.38$8,437$1,384.80+$20416.47MSLMXF
5$655,001,400,109$633,155,770,552.78$9,013$1,875.40+$655001.39MSLMXF
6$19,684,873,685,924$18,984,022,187,807.58$10,306$2,680.72+$19684873.68MSLMXF
7$554,268,607,828,726$533,205,792,984,787.70$12,820$4,101.38+$554268607.82MSLMXF
8$14,624,393,933,143,850$14,031,326,522,767,112.00$17,673$6,826.70+$14624393933.13MSLMXF
9$361,645,272,965,188,740$345,997,171,456,724,800.00$27,543$12,591.86+$361645272965.16MSLMXF
10$8,383,345,271,821,568,000$7,996,384,829,748,816,000.00$49,560$26,258.71+$8383345271821.52MSLMXF

SLMXF vs PFE: Complete Analysis 2026

SLMXFStock

Slam Exploration Ltd., a resource company, engages in the acquisition, exploration, and development of exploration and evaluation properties in Canada. It primarily explores for gold, silver, base metal, and rare earth metals. The company's flagship project is the Menneval gold project that consists of 8 mineral claims comprising 580 claim units covering an area of 12,450 hectares situated in New Brunswick. The company also holds interest in Benjamin REE property; Birch Lake project; Eighteen Mile property; Jake Lee Gold property; McNair property; Mt. Blair Property; Mt. Victor property; and Flume Ridge Gold property, which comprises 76 claim units covering 1,717 hectares in 2 separate claims located in New Brunswick. In addition, it holds interests in Stephenson Lake Gold project; Wilson Brook Gold project; York Gold project; Gold Brook property; and Pug Hole property. Slam Exploration Ltd. was incorporated in 1996 and is headquartered in Miramichi, Canada.

Full SLMXF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SLMXF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLMXF vs SCHDSLMXF vs JEPISLMXF vs OSLMXF vs KOSLMXF vs MAINSLMXF vs JNJSLMXF vs MRKSLMXF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.